ASTRAGALOSIDE III FROM ASTRAGALUS MEMBRANACEUS ANTAGONIZES BREAST CANCER GROWTH

Authors

  • Shouman Wang
  • Lili Tang
  • Feiyu Chen

DOI:

https://doi.org/10.21010/ajtcam.v12i3.23

Keywords:

breast cancer, Astragaloside III, apoptosis, treatment,

Abstract

Background: Astragaloside III has been used to treat different cancers; however their effect on breast cancer remains unknown. Materials and methods: The present study examined the effects of Astragaloside III from Astragalus membranaceus on breast cancer cell lines in vitro as well as xenograft in vivo. Results: The results showed that the Astragaloside III could effectively reduce cancer cell survival in vitro and inhibit the tumor growth in vivo. The potential mechanism is the induction of cell apoptosis signaling pathways. Conclusion: We believe that Astragaloside III provides a new therapeutic tool to treat breast cancer.

Author Biographies

Shouman Wang

Drug Research & Production Unit, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria

Lili Tang

Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, People’s Republic of China.

Downloads

Published

2015-04-05

How to Cite

Wang, S., Tang, L., & Chen, F. (2015). ASTRAGALOSIDE III FROM ASTRAGALUS MEMBRANACEUS ANTAGONIZES BREAST CANCER GROWTH. African Journal of Traditional, Complementary and Alternative Medicines, 12(3), 183–186. https://doi.org/10.21010/ajtcam.v12i3.23

Issue

Vol. 12 No. 3 (2015)

Section

Research Papers

License

Copyright: Creative Commons Attribution CC.

This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. View License Deed | View Legal Code Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications.